Evidence map›Paper›PMID 40830820›Full record

ArticleEuropean journal of medical research2025

TET1 methylation and mRNA expression in renal cell carcinoma: implications for tumor staging and prognosis.

Maomao Li, Liping Xin, Yi Huang, Jingjing Yu, Guobin Weng

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maomao LiDepartment of Urology, Ningbo Urology and Nephrology Hospital, Ningbo, 315100, Zhejiang, China.
Liping XinDepartment of Rehabilitation, Ningbo Urology and Nephrology Hospital, Ningbo, 315100, Zhejiang, China.
Yi HuangNingbo Key Laboratory of Nervous System and Brain Function, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, Zhejiang, China.
Jingjing YuDepartment of Pathology, Ningbo Urology and Nephrology Hospital, Ningbo, 315100, Zhejiang, China. nbyjj1028@163.com.
Guobin WengDepartment of Urology, Ningbo Urology and Nephrology Hospital, Ningbo, 315100, Zhejiang, China. wengguob123@163.com.

Funding

Medicine and Health Project of Zhejiang Province 2019KY630Ningbo Yinzhou District Science and Technology Bureau Agricultural Society Project 2024AS061
6 · The paper itself

Abstract

backgroundRenal cell carcinoma (RCC) is a prevalent cancer characterized by intricate molecular mechanisms that contribute to its advancement. Epigenetic alterations, particularly DNA methylation, play a critical role in cancer development. This research examines TET1 gene methylation's involvement in RCC development and its viability as a diagnostic marker.

methodsWe evaluated TET1 expression in 532 RCC tumor samples and 72 adjacent normal tissues using data from the TCGA database. A clinical case-control study involving 40 RCC patients and matched controls was conducted to evaluate TET1 methylation at nine CpG sites in the promoter region using pyrosequencing. The relationship between TET1 methylation, clinical indicators, and tumor markers was evaluated by combining clinical samples and cell experiments. The diagnostic efficacy of TET1 methylation and mRNA expression levels were assessed using ROC curve analysis.

resultsTET1 expression was notably reduced in RCC tumor tissues relative to adjacent normal tissues (P < 0.05) and was elevated in early stage (T1 and stage 1) tumors compared to advanced stages. RCC patients exhibited significantly higher methylation levels at all nine CpG sites and in the mean methylation level compared to controls (P < 0.001). Gender-specific analysis revealed lower TET1 methylation levels in males compared to females, with significant differences at CpG1-CpG8 sites (P < 0.05). TET1 methylation levels were positively correlated with tumor stage, tumor size, and serum markers, such as CA125, NSE and Ki67 (P < 0.05), and significantly negatively correlated with TET1 expression (r = - 0.665, P < 0.001). ROC curve analysis showed that the combination of TET1 average methylation and mRNA expression level (AUC = 0.876) had a high diagnostic efficacy. The levels of TET1 and p21 in RCC patients and 786-O cells were significantly reduced, and the level of Ki67 was significantly increased, suggesting that TET1 methylation may participate in the mechanism of malignant proliferation of RCC tumor cells by regulating p21 and Ki67.

conclusionsThis study underscores the importance of TET1 methylation in RCC progression and its promise as an early stage diagnostic biomarker, and may be involved in the mechanism of malignant proliferation of RCC cells. These findings offer fresh perspectives on RCC's epigenetic regulation and highlight TET1's potential in therapy and diagnosis.

Indexed as

Carcinoma, Renal CellDNA MethylationKidney NeoplasmsMixed Function OxygenasesProto-Oncogene ProteinsRNA, MessengerAdultAgedBiomarkers, TumorCase-Control StudiesCpG IslandsEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMaleBiomarkers, TumorMixed Function OxygenasesProto-Oncogene ProteinsRNA, MessengerTET1 protein, humanBiomarkerDNA methylationRenal cell carcinomaTET1Tumor stage

Identifiers

PMID40830820
PMCPMC12366327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.